Welcome to Cardiology Today – Recorded September 29, 2025. This episode summarizes 5 key cardiology studies on topics like angiotensin two and fibroblast activation. Key takeaway: Septin4 Inhibition Reverses Cardiac Fibrosis.
Article Links:
Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload. (Circulation research)
Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. (Circulation research)
Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice. (Circulation research)
Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. (Circulation research)
Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. (European journal of heart failure)
Full episode page: https://podcast.explainheart.com/podcast/septin4-inhibition-reverses-cardiac-fibrosis-09-29-25/
Featured Articles
Article 1: Septin4 Regulates Cardiac Fibrosis After Pressure Overload.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40960950
Summary: This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.
Article 2: DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40910184
Summary: Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.
Article 3: Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40899274
Summary: in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.
Article 4: Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release.
Journal: Circulation research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40899273
Summary: The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.
Article 5: Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population.
Journal: European journal of heart failure
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40999971
Summary: Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease.
Transcript
Today’s date is September 29, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Septin4 Regulates Cardiac Fibrosis After Pressure Overload. This study found that Septin4, a small G.T.P.ase, plays a crucial role in regulating cardiac fibrosis following pressure overload in the heart. Specifically, Septin4 deficiency reduced cardiac fibroblast activation and collagen deposition, leading to improved cardiac function and reduced heart failure progression in mice subjected to transverse aortic constriction. These findings suggest that targeting Septin4 could be a potential therapeutic strategy for mitigating cardiac fibrosis and heart failure.
Article number two. DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. Researchers demonstrated that DWORF, a cardiac microprotein, enhances sarco/endoplasmic reticulum calcium ATPase isoform 2a activity, improving calcium reuptake in cardiomyocytes. Gene therapy delivery of DWORF in a heart failure model improved cardiac calcium handling, mitochondrial function, and overall cardiac performance. This indicates that DWORF gene therapy represents a promising approach for treating heart failure by restoring calcium homeostasis.
Article number three. Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of End.M.T. in Hypertensive Mice. This research showed that partial reprogramming of endothelial cells can attenuate endothelial-to-mesenchymal transition in hypertensive mice. A single short pulse of reprogramming factors led to decreased blood pressure, improved endothelial function, and reduced small artery remodeling. This suggests that endothelial cell reprogramming could be a therapeutic strategy for hypertension by targeting endothelial dysfunction.
Article number four. Calcium Oscillations Within Juxtaglomerular Cell Clusters Control Renin Release. The study revealed that calcium oscillations within juxtaglomerular cell clusters are essential for controlling renin release, which regulates blood pressure and fluid-electrolyte balance. Juxtaglomerular cells respond to changes in blood pressure by modulating these calcium oscillations, thereby influencing renin secretion and subsequent angiotensin two production. Understanding these calcium signaling mechanisms could provide new targets for managing hypertension and related disorders.
Article number five. Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. Analysis of a large population in Germany found that metabolic dysfunction-associated steatotic liver disease is significantly associated with an increased risk of major adverse cardiovascular events and overall mortality. Patients with metabolic dysfunction-associated steatotic liver disease had a higher incidence of cardiovascular events, highlighting the importance of cardiovascular risk management in this population. These findings underscore the need for integrated approaches addressing both liver and cardiovascular health in individuals with metabolic dysfunction-associated steatotic liver disease.
Thank you for listening. Don’t forget to subscribe.
Keywords
angiotensin two, fibroblast activation, calcium handling, renin release, S.E.R.C.A.2a, cardiac fibrosis, hypertension, endothelial cells, liver enzymes, DWORF, calcium oscillations, ventricular remodeling, heart failure, reprogramming, Septin4, mortality, endothelial-to-mesenchymal transition, blood pressure, cardiovascular events, gene therapy, juxtaglomerular cells, metabolic dysfunction-associated steatotic liver disease, cardiovascular risk.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow
The post Septin4 Inhibition Reverses Cardiac Fibrosis 09/29/25 first appeared on Cardiology Today.